A Phase 1 interventional study of Dotarem® IV injection at 0.1 mmol/kg in End-stage Renal Failure, sponsored by Guerbet. Completed at 1 site in Belgium. Open to participants aged 18 Years to 95 Years. Per ClinicalTrials.gov, last updated 2015-07-08.
Sponsored by Guerbet · Phase 1 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 62 studies in Kidney Failure, Chronic with a site in Belgium — 8 open to participants now, 14 under way, 3 of them phase 3. Kidney Failure, Chronic · Belgium.
Among the 62 studies in Kidney Failure, Chronic with a site in Belgium, this one is the 39th largest by enrollment of the 45 interventional ones that give a count, is one of 4 that started in 2011, is one of 2 in phase 1, and was the 16th registered.
2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.
Browse Kidney Failure, Chronic studies →8 of the 62 studies in Kidney Failure, Chronic with a site in Belgium are open now. Recruiting first, the newest first:
Regeneron Pharmaceuticals · Sites in Belgium
Ages 18+
Universitair Ziekenhuis Brussel · Sites in Belgium
Ages 18+
CSL Behring · Sites in Belgium, United States, Argentina and 32 more countries
Ages 18+
Brugmann University Hospital · Sites in Belgium
Ages 18+ · Healthy volunteers
Universitair Ziekenhuis Brussel · Sites in Belgium, Netherlands
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 95 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
62 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 6 · Phase 3 10 · Phase 4 5
First in 1994; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 57 across 1,572 interventional studies indexed under Kidney Failure, Chronic.
Median enrollment 71 across the 45 interventional studies, 150 across the 17 observational. Of the 43 that completed or were terminated, 14 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 62 have an industry lead sponsor. The 10 most frequent:
Guerbet is the lead sponsor of 42 studies on the registry; 2 are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 7 (88%) have results posted.
Guerbet has 1 study filed under Kidney Failure, Chronic — fewer than ten, so there is no comparison to draw.
2 of the studies in Kidney Failure, Chronic with a site in Belgium that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05970172Phase 3Astellas Pharma Global Development, Inc.A Study of Roxadustat to Treat Anemia in Children and Teenagers With Chronic Kidney Disease | 2027-10-30 |
| NCT07759167Regeneron PharmaceuticalsStudy of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis | 2027-04-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 62 studies in Kidney Failure, Chronic with a site in Belgium, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the dialysability of Dotarem®, after an IV injection of 0.1 mmol/kg in patients with chronic renal failure who require hemodialysis treatment.
Ten adult patients suffering from end stage renal failure and requiring hemodialysis treatment for 3 times were enrolled. Patients received a single dose of Dotarem® at 0.1 mmol/kg before being submitted to hemodialysis to assess the dialysability of Dotarem® . After injection of Dotarem®, 3 sessions of hemodialysis were performed as follows:
The first hemodialysis session started between 1 to 2 h after the injection; The second hemodialysis session occurred 2 days (i.e., 48 ± 2 h) after the Dotarem® injection; The third hemodialysis session occurred 4 days (i.e., 96 ± 4 h) after the Dotarem® injection.
The decrease in serum Dotarem® concentration was assessed after each hemodialysis session. Safety assessments included adverse events (AEs), vital signs, injection-site tolerance, and laboratory assessments.Two safety follow-up visits were performed: one 3 weeks (± 2 days) and one 3 months (± 4 days) after the Dotarem® injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female, aged ≥18 years
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Male or female subjects, aged ≥18 years,suffering from end-stage renal failure and requiring hemodialysis treatment 3 times per week, were submitted to a single Dotarem® IV injection at 0.1 mmol/kg before being submitted to 3 hemodialysis sessions to assess the decrease of Dotarem® concentration in the blood.
Drug: Dotarem® IV injection at 0.1 mmol/kg
Drug page: Gadoterate meglumine
Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
Also known as: gadoterate meglumine, gadoteric acid
Dialysability of Dotarem® in Dialysed Patients
To evaluate the decrease in seric concentration of gadolinium, after each hemodialysis session of patients injected with 0.1 mmol/kg of Dotarem® . The percent change of gadolinium concentration is calculated by estimating the amount of serum gadolinium before and after each hemodialysis session. Calculations are performed only for subjects with concentration above the lower limit of quantification (LLQ)
Time frame: Dotarem® dialysability assessed up to 4 days after Dotarem® administration
Safety of Dotarem® in Dialysed Patients Evaluated by the Number of Patients Experiencing Adverse Events.
To evaluate the biological and clinical safety of Dotarem® by assessing vital signs, biological parameters, injection-site tolerance, through a 4-day post injection follow-up, adverse events through a 3-week post injection period and serious adverse events through a 3-month post injection period.
Time frame: Safety assessed from patients inclusion until the last follow-up visit 3 months after Dotarem® administration
| Milestone | Dotarem® Injected Patients |
|---|---|
| Started | 10 |
| Completed | 10 |
| Not completed | 0 |
To evaluate the decrease in seric concentration of gadolinium, after each hemodialysis session of patients injected with 0.1 mmol/kg of Dotarem® . The percent change of gadolinium concentration is calculated by estimating the amount of serum gadolinium before and after each hemodialysis session. Calculations are performed only for subjects with concentration above the lower limit of quantification (LLQ)
| percent change in Gd concentration | Dotarem® Injected Patients |
|---|---|
| Percent change at 0.5h after first hemodialysis | -88.2 (-93.5 to -84.7) |
| Percent change at 1.5h after first hemodialysis | -93.4 (-95.7 to -90.3) |
| Percent change at 4h after first hemodialysis | -97.1 (-99.1 to -90.5) |
| Percent change at 4h after second hemodialysis n=7 | -94.8 (-97.7 to -84.8) |
| Percent change at 4h after third hemodialysis n=2 | -89.9 (-94.9 to -85.0) |
To evaluate the biological and clinical safety of Dotarem® by assessing vital signs, biological parameters, injection-site tolerance, through a 4-day post injection follow-up, adverse events through a 3-week post injection period and serious adverse events through a 3-month post injection period.
| participants | Dotarem® Injected Patients |
|---|---|
| Safety of Dotarem® in Dialysed Patients Evaluated by the Number of Patients Experiencing Adverse Events. | 8 |
Evaluation of the decrease in seric concentration of gadolinium, 4h after the second hemodialysis session of patients injected with 0.1 mmol/kg of Dotarem®. The percent change of gadolinium concentration was estimated from the concentration of gadolinium after Dotarem® injection. Only subjects with gadolinium concentration above the lower limit of quantification (LLQ) were kept for analysis.
| Percent change in Gd concentration | Dotarem® Injected Patients |
|---|---|
| Percent Change in Gadolinium Serum Concentration 4h After Second Hemodialysis Session, Estimated From Subjects With Concentration Data Above the Limit of Detection | -99.5 (-99.8 to -98.6) |
The evaluation of the decrease in seric concentration of gadolinium, 4h after the third hemodialysis session of patients injected with 0.1 mmol/kg of Dotarem®. The percent change of gadolinium concentration was estimated from the concentration of gadolinium after Dotarem® injection. Only subjects with gadolinium concentration above the lower limit of detection were kept for analysis.
| percent change in Gd concentration | Dotarem® Injected Patients |
|---|---|
| Percent Change in Gadolinium Serum Concentration 4h After Third Hemodialysis Session, Estimated From Subjects With Concentration Data Above the Limit of Detection | -99.7 (-99.8 to -99.7) |
Collected over Safety assessment was performed at the day 1, day 2, and day 4 after Dotarem® injection. Two safety follow-up visits were performed at 3 weeks (+/- 2 days) and at 3 months (+/- 4 days) after Dotarem® injection.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dotarem® Injected Patients | — | 4/10 (40%) | 8/10 (80%) |
| Event | Dotarem® Injected Patients |
|---|---|
| moderate sepsisInfections and infestations | 2/10 |
| severe respiratory failureRespiratory, thoracic and mediastinal disorders | 1/10 |
| severe peripheral ischemiaVascular disorders | 1/10 |
| moderate thrombocytopeniaBlood and lymphatic system disorders | 1/10 |
| severe urosepsisInfections and infestations | 1/10 |
| Dialysis device insertionSurgical and medical procedures | 1/10 |
| NephrectomySurgical and medical procedures | 1/10 |
| Event | Dotarem® Injected Patients |
|---|---|
| HypotensionVascular disorders | 5/10 |
| HeadacheNervous system disorders | 3/10 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 3/10 |
| AnemiaBlood and lymphatic system disorders | 1/10 |
| Abdominal painGastrointestinal disorders | 1/10 |
| influenza-like illnessGeneral disorders | 1/10 |
| thirstGeneral disorders | 1/10 |
| Procedural painInjury, poisoning and procedural complications | 1/10 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 1/10 |
| Musculoskeletal painMusculoskeletal and connective tissue disorders | 1/10 |
No statistical calculation of sample size was done. According to the literature, a sample of 10 patients was judged sufficient to evaluate the dialysability of Dotarem®.
| Age, Categorical(Participants) | Dotarem®-Injected Patients |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 5 |
| >=65 years | 5 |
| Age, Continuous(years) | Dotarem®-Injected Patients |
|---|---|
| Median | 64.0 (31 to 79) |
| Sex: Female, Male(Participants) | Dotarem®-Injected Patients |
|---|---|
| Female | 5 |
| Male | 5 |
| Region of Enrollment(participants) | Dotarem®-Injected Patients |
|---|---|
| Belgium | 10 |
The record gives a start of Nov 2011, a primary completion of Mar 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2015, 3 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gadoterate meglumine